動物模型市場－全球產業規模、佔有率、趨勢、機會與預測：按動物類型、應用、通路、地區和競爭格局分類，2021-2031年

全球動物模型市場預計將從 2025 年的 19.7 億美元大幅成長到 2031 年的 32.2 億美元，複合年成長率為 8.53%。

囓齒動物、靈長類動物和斑馬魚等非人類生物體在科學研究中發揮著至關重要的作用，它們能夠模擬人類生物系統和疾病病理，並用於開發醫療干預措施。市場擴張的主要驅動力是慢性疾病和感染疾病的日益普遍，這些疾病和感染需要進行廣泛的臨床前試驗，以及嚴格的監管要求，這些要求在進行人體臨床試驗之前必須進行全面的安全性和毒性評估。製藥和生技公司不斷增加的研發投入也進一步推動了這一成長。根據BioSpace在2025年5月發布的報告，全球製藥公司在2024年的研發投入約2,880億美元。如此龐大的投資確保了對體內系統穩定的需求，查爾斯河實驗室2024年40.5億美元的銷售額也印證了這一點。政府資助也發揮著重要作用，例如，美國國立衛生研究院（NIH）在2025財政年度獲得了469.95億美元的預算。這為學術和公共研究提供了必要的支持。

然而，由於對動物福利的倫理監管日益嚴格以及國際法規的日益嚴苛，市場面臨著巨大的挑戰。這些法規越來越重視「3R」原則（替代、減少、改進）。這些壓力導致合規成本上升、體內試驗核准週期延長，以及研究預算轉向非動物試驗方法，最終導致動物使用量下降。根據英國生物科學產業聯盟預測，到2025年，英國的動物使用量預計將下降至2019年水準的約77%。同時，一些關鍵趨勢正在重塑該領域。人源化免疫系統模型的應用正在加速，尤其是在免疫腫瘤學領域，其臨床應用價值日益凸顯。百奧賽汀計畫在2024年底前，在其RenMice平台上完成約200項治療性抗體的合作開發和授權協議。此外，由於內部維護基因係的複雜性和成本高昂，企業正逐漸將模型建構外包給合約研究組織（CRO）。查爾斯河實驗室的研究模型和服務部門就清楚地體現了這種外包趨勢，該部門累計2024年的年收入將達到8.294億美元，這表明該行業對專業外部供應商的依賴性仍然存在。

市場促進因素

市場成長主要得益於製藥和生技公司研發投入的增加。這些公司尋求利用體內系統對新療法進行可靠的臨床前檢驗。這種資金投入確保了用於毒性和療效測試的各種動物物種的穩定供應。例如，BioSpace 2025年5月的報告指出，全球製藥公司在2024年研發投入近2,880億美元，凸顯了對動物模型的高度依賴。此外，政府對生物醫學研究的資助激增也使該行業受益，為大量使用基因改造和疾病特異性模型的學術機構和公共機構提供了必要的資金。例如，Congress.gov在2025年12月報道稱，美國國立衛生研究院（NIH）在2025會計年度獲得了469.95億美元的預算，這起到了穩定作用，確保了津貼研究對生物工具的持續需求。

市場挑戰

全球動物模型市場擴張的主要障礙在於國際上對動物福利的嚴格監管以及日益嚴格的倫理審查。這些法規結構日益強化「3R原則」（替代、減少、改進），並強制要求系統性地減少科學實驗中活體動物的使用。在此背景下，製藥和生技公司被迫面對不斷上漲的合規成本和更長的體內試驗核准週期，這降低了它們購買動物模型的意願。由於研發預算被重新分配到合規和替代測試方法上，交易量有所下降。英國生物科學產業聯盟的一份報告顯示，到2025年，英國使用動物的科學實驗數量將下降至2019年水準的約77%，這將嚴重抑制獲利能力。

市場趨勢

市場正經歷著變革性的轉變，尤其是人源化免疫系統模型的加速應用。這些先進的生物系統透過以功能性的人源成分取代小鼠來源的免疫成分，對於提高臨床前研究成果轉化為人體臨床試驗的可能性至關重要，尤其是在腫瘤免疫學領域。百奧賽圖公司2025年6月發布的新聞稿從數量上印證了這一趨勢，該新聞稿顯示，截至2024年底，該公司已就其RenMice人源化模型平台簽署了約200項治療性抗體的合作開發和許可協議。此外，將模型建構外包給合約研究組織（CRO）的策略轉變也十分明顯。這一轉變源於企業內部維護複雜基因係的日益複雜和成本不斷上升，使得製藥公司能夠利用專業技術專長，同時將固定的基礎設施成本轉化為可變的服務費用。根據 2025 年 2 月的一份報告，查爾斯河實驗室的研究模型和服務 (RMS) 部門在 2024 年累計了8.294 億美元的年銷售額，是該行業持續依賴外包模型管理和生產能力的典型例子。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球動物模型市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 動物種類（小鼠、大鼠、天竺鼠、兔子、倉鼠、其他）
  • 依應用領域（癌症、免疫系統疾病、感染疾病等）
  • 銷售管道（製藥和生物技術公司、學術研究機構、合約研究組織）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美動物模型市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲動物模型市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區動物模型市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東與非洲動物模型市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲動物模型市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球動物模型市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Charles River Laboratories International Inc.
• The Jackson Laboratory
• Taconic Biosciences, Inc.
• Janvier Labs SAS
• HBM Holdings Limited
• Crown Bioscience Inc.
• Inotiv Inc.
• Biocytogen Pharmaceuticals（Beijing）Co., Ltd.
• BioSpherix, Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Animal Model Market is projected to grow substantially from USD 1.97 billion in 2025 to USD 3.22 billion by 2031, exhibiting an 8.53% compound annual growth rate. These non-human organisms, including rodents, primates, and zebrafish, are crucial for scientific research, replicating human biological systems and disease pathologies to develop medical interventions. Market expansion is primarily driven by the escalating prevalence of chronic and infectious diseases necessitating extensive preclinical testing, coupled with stringent regulatory mandates requiring comprehensive safety and toxicity assessments prior to human clinical trials. Further bolstering this growth is the increasing research and development (R&D) expenditure by pharmaceutical and biotechnology companies, with global drugmakers investing nearly $288 billion in R&D in 2024, as reported by BioSpace in May 2025. This significant investment ensures a steady demand for in vivo systems, a fact underscored by Charles River Laboratories' 2024 revenue of $4.05 billion. Government funding also plays a vital role, exemplified by the National Institutes of Health (NIH) receiving $46.995 billion for FY2025, which provides essential support for academic and public research.

However, the market faces a significant challenge due to escalating ethical scrutiny and stringent international regulations on animal welfare, which increasingly promote the '3Rs' principles-Replacement, Reduction, and Refinement. These pressures lead to higher compliance costs and longer approval times for in vivo studies, redirecting research budgets towards non-animal testing methods and resulting in reduced animal usage, such as the UK's drop to approximately 77% of 2019 levels by 2025 according to the UK Bioscience Sector Coalition. Concurrently, the sector is being reshaped by key trends. The accelerated adoption of humanized immune system models is enhancing translatability, especially in immuno-oncology, with Biocytogen executing around 200 therapeutic antibody co-development and licensing agreements for its RenMice platforms by late 2024. Additionally, there's a strategic shift towards outsourcing model generation to Contract Research Organizations (CROs), driven by the complexity and cost of maintaining genetic lines in-house. This outsourcing trend is evident in Charles River Laboratories' Research Models and Services segment generating $829.4 million in annual revenue in 2024, reflecting sustained industry reliance on specialized external providers.

Market Driver

The market's growth is predominantly fueled by the increasing research and development (R&D) investments from pharmaceutical and biotechnology companies, which demand robust preclinical validation using in vivo systems for novel therapeutics. This financial commitment ensures a consistent supply chain for various animal species used in toxicology and efficacy studies. For instance, drugmakers globally invested nearly $288 billion in R&D in 2024, as noted by BioSpace in May 2025, underscoring the reliance on animal models. The sector also benefits from a surge in government funding for biomedical research, providing essential liquidity for academic and public institutions that extensively utilize genetically modified and disease-specific models. The National Institutes of Health (NIH), for example, received $46.995 billion for fiscal year 2025, according to Congress.gov in December 2025, which acts as a stabilizing force, ensuring continuous demand for biological tools in grant-funded studies.

Market Challenge

A significant impediment to the Global Animal Model Market's expansion stems from stringent international regulations concerning animal welfare and intensifying ethical scrutiny. These regulatory frameworks increasingly enforce the '3Rs' principles-Replacement, Reduction, and Refinement-mandating a systematic decrease in live animal use for scientific experimentation. This environment compels pharmaceutical and biotechnology entities to face higher compliance costs and prolonged approval timelines for in vivo studies, consequently discouraging the procurement of animal models. This redirection of research budgets toward compliance and alternative testing methods has led to reduced transaction volumes, with scientific procedures involving animals in the UK dropping to approximately 77% of 2019 levels by 2025, as reported by the UK Bioscience Sector Coalition, thereby dampening revenue potential.

Market Trends

The market is undergoing transformative shifts, notably with the accelerated adoption of humanized immune system models. These advanced biological systems are becoming vital for improving the translatability of preclinical studies to human clinical outcomes, particularly in immuno-oncology, by replacing murine immune components with functional human counterparts. This trend is quantitatively demonstrated by Biocytogen's execution of approximately 200 therapeutic antibody co-development and licensing agreements for its RenMice humanized model platforms by the end of 2024, as per their June 2025 press release. Additionally, a strategic shift towards outsourcing model generation to Contract Research Organizations (CROs) is evident. This move, driven by the increasing complexity and cost of maintaining sophisticated genetic lines in-house, allows pharmaceutical developers to convert fixed infrastructure costs into variable service expenditures while leveraging specialized technical expertise. Charles River Laboratories' Research Models and Services (RMS) segment, which generated $829.4 million in annual revenue in 2024, as reported in February 2025, exemplifies the industry's sustained reliance on outsourced model management and production capabilities.

Key Market Players

• Charles River Laboratories International Inc.
• The Jackson Laboratory
• Taconic Biosciences, Inc.
• Janvier Labs S.A.S.
• HBM Holdings Limited
• Crown Bioscience Inc.
• Inotiv Inc.
• Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
• BioSpherix, Ltd

Report Scope

In this report, the Global Animal Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Model Market, By Animal Type

• Mice
• Rat
• Guinea Pigs
• Rabbits
• Hamsters
• Others

Animal Model Market, By Application

• Cancer
• Immunological Disease
• Infectious Disease
• Others

Animal Model Market, By Distribution Channel

• Pharmaceutical & Biotechnology Companies
• Academic Research Institute
• Contract Research Organization

Animal Model Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Model Market.

Available Customizations:

Global Animal Model Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Animal Model Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Animal Type (Mice, Rat, Guinea Pigs, Rabbits, Hamsters, Others)
  • 5.2.2. By Application (Cancer, Immunological Disease, Infectious Disease, Others)
  • 5.2.3. By Distribution Channel (Pharmaceutical & Biotechnology Companies, Academic Research Institute, Contract Research Organization)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Animal Model Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Animal Type
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Animal Model Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Animal Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Animal Model Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Animal Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Animal Model Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Animal Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Animal Model Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Animal Type
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Animal Model Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Animal Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Animal Model Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Animal Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Animal Model Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Animal Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Animal Model Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Animal Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Animal Model Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Animal Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Animal Model Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Animal Type
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Animal Model Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Animal Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Animal Model Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Animal Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Animal Model Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Animal Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Animal Model Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Animal Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Animal Model Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Animal Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Animal Model Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Animal Type
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Animal Model Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Animal Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Animal Model Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Animal Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Animal Model Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Animal Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. South America Animal Model Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Animal Type
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Animal Model Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Animal Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Animal Model Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Animal Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Animal Model Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Animal Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Animal Model Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Charles River Laboratories International Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. The Jackson Laboratory
• 15.3. Taconic Biosciences, Inc.
• 15.4. Janvier Labs S.A.S.
• 15.5. HBM Holdings Limited
• 15.6. Crown Bioscience Inc.
• 15.7. Inotiv Inc.
• 15.8. Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
• 15.9. BioSpherix, Ltd

16. Strategic Recommendations

17. About Us & Disclaimer